Trofinetide US patent protections extended to March 2041
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This patent relates to the treatment of Rett syndrome and is expected to provide additional protection for the drug in the United States. Trofinetide is marketed in the US as DAYBUE® and DAYBUE® STIX for treating Rett syndrome in patients aged two years and older. Neuren is also developing other drug therapies for serious neurological disorders with limited treatment options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Pause in Trading
- Update - Dividend/Distribution - NEU
- Corporate Presentation, 2 September 2026
- Dividend/Distribution - NEU
- Investor presentation, 26 August 2026
Later from Neuren Pharmaceuticals
- FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE
- Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals